Psoriatic Arthritis (PsA) Treatment Market Size to Reach USD 50.45 Bn by 2034

Vantage Market Research releases its latest comprehensive report on the ‘Psoriatic Arthritis (PsA) Treatment Market’ with a forecast period of 2025-2034. In 2023, the global Psoriatic Arthritis (PsA) Treatment Market size was USD 22.11 Billion, and is calculated at USD 24.01 billionin 2024. The PsA treatment market is projected to reach USD 50.45 billion in 2034, and register a revenue CAGR of 8.6% over the forecast period (2025-2034).

Market Overview:

The global Psoriatic Arthritis (PsA) treatment market has been registering a steady revenue growth rate, with factors such as rising prevalence of arthritis and awareness about available treatments, advances in biologic and biosimilar therapies, and new approaches for managing PsA symptoms and slowing disease progression gaining traction. Also, innovations like self-administered injectable drugs are making treatment more accessible and convenient, and prompting incline in adoption rates of various drugs and formulations.

Research and development and increasing investment by pharmaceutical companies into new therapies with fewer side effects and better patient outcomes, as well as improvements in diagnostic tools are enabling earlier detection of PsA, which allows for timely intervention and a better chance of successful treatment. Supportive government policies, especially in regions with high PsA prevalence, are helping improve access to these therapies, further boosting market growth. The rise of telemedicine and online pharmaceutical sales has made it easier for patients to access both treatments and consultations, leading to broader treatment uptake.

Rising healthcare spending and rapidly aging global population are also key factors driving demand for managing age-related conditions like PsA and others. Psoriatic Arthritis is part of the spondyloarthritis spectrum, which includes related conditions like ankylosing spondylitis, reactive arthritis, and arthritis associated with inflammatory bowel disease. Symptoms of PsA typically include joint pain, swelling, and tenderness, as well as psoriatic skin lesions. While the exact causes of PsA remain unclear, genetic and environmental factors appear to play a role. The condition most commonly affects individuals aged 30 to 50 years, and without treatment, it can lead to permanent joint damage and disability.

Significant progress is being made in biologic and biosimilar medications and this is serving to open avenues for patients to access highly effective treatment options with fewer side effects than traditional drugs. These therapies are designed to target specific inflammatory pathways associated with PsA, making them a preferred choice among healthcare providers and patients. Also, demand for these therapies is expected to grow as demonstration and proof of positive outcomes become more known and reach wider patient bases and pools. This can also result in increased accessibility and easier affordability through biosimilar competition.

Ongoing and extensive R&D activities in PsA treatment are resulting in a continuous pipeline of innovative products, further enhancing market growth. Pharmaceutical companies are focusing on developing advanced therapies that offer improved efficacy and more convenient administration methods. 

Some Key Takeaways:

• North America led in terms of revenue share due to high prevalence of PsA, strong healthcare infrastructure, and extensive R&D efforts. 
• The US dominated the other country-level markets in North America in 2023.
• In Europe, countries such as Germany, the UK, and France lead in terms of adoption of various treatments and therapies, supported by favorable healthcare policies and high diagnostic rates.
• Asia Pacific market is expected to register a rapid growth rate over the forecast period, driven by rising disease awareness, expanding healthcare access, and government support.
• Among the drug class segments, the biologics and biosimilars segment is expected to account for largest revenue share over the forecast period.
• Among the type of treatment segments, the prescription-based segment is expected to maintain dominance in terms of revenue share over the forecast period.
• Among the route of administration segments, the injectable segment accounted for largest revenue share in 2023.
• Among the distribution channel segments, the hospital pharmacies segment is expected to continue to account for largest revenue share over the forecast period. 
• The competitive landscape in the global Psoriatic Arthritis (PsA) treatment market is intense, as leading pharmaceutical companies strive to innovate and expand their consumer base. 
• Key players include AbbVie, Amgen, Pfizer, Novartis, Eli Lilly, and Janssen, all of which have invested substantially in R&D to develop advanced biologics and targeted therapies.

Company List:

• AbbVie Inc.
• Amgen Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Pfizer Inc.
• Bristol-Myers Squibb
• Novartis AG
• UCB S.A.
• Eli Lilly and Company
• Biogen
• Merck KGaA
• Sanofi
• Teva Pharmaceuticals
• Fujifilm Kyowa Kirin Biologics
• Samsung Bioepis
• Sun Pharmaceutical Industries

Recent Developments:

• October 22, 2024: Alvotech and Teva Pharmaceuticals, which is an US affiliate of Teva Pharmaceutical Industries Ltd., announced that it has secured approval from the U.S. Food and Drug Administration (FDA) for SELARSDI (ustekinumab-aekn) in a new presentation, 130 mg/26 mL (5 mg/mL) solution in a single-dose vial for intravenous infusion. Following this development, the company strengthens its biosimilar development and enhanced the psoriatic arthritis treatment, as this is the second ustekinumab biosimilar to be approved by the FDA, following Amgen's WEZLANA (ustekinumab-auub) in October 2023.
• September 23, 2024: UCB, which is a global biopharmaceutical company, announced it had received approval from the U.S. Food and Drug Administration (FDA) for a 2 mL pre-filled syringe and pre-filled autoinjector, each containing 320 mg of BIMZELX (bimekizumab-bkzx). On 27 December 2023, the company announced securing approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for BIMZELX (bimekizumab) for the treatment of adults with psoriatic arthritis, non-radiographic axSpA (nr-axSpA), and ankylosing.

Global Psoriatic Arthritis (PsA) Treatment Market Segmentation:

By Drug Class:

• Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Biologics and Biosimilars
• Corticosteroids
• Others (PDE4 Inhibitors)

By Type of Treatment:

• Prescription-based
• Over-the-Counter (OTC)

By Route of Administration:

• Oral
• Injectable
• Topical

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
  • United States

Regional Segmentation: 

North America

• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Rest of Latin America 

Middle East & Africa

• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA